• OPEN AN ACCOUNT
Indian Indices
Sensex
78,918.90 -1,097.00
( -1.37%)
Global Indices
Nasdaq
47,518.20 -457.55
(-0.95%)
Dow Jones
6,761.35 -90.36
(-1.32%)
Hang Seng
55,600.46 322.40
(0.58%)
Nikkei 225
10,286.75 -127.19
(-1.22%)
Forex
USD-INR
91.74 -0.39
(-0.42%)
EUR-INR
106.47 -0.59
(-0.55%)
GBP-INR
122.42 -0.61
(-0.50%)
JPY-INR
0.58 0.00
(-0.46%)

EQUITY - MARKET SCREENER

Mafia Trends Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
543613
INE0KQQ01011
17.9078842
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
6.83
2.78
EPS(TTM)
Face Value()
Div & Yield %
0.92
10
1.59
 

Marksans Pharma’s arm gets USFDA approval for Loperamide Hydrochloride 2mg tablets
Nov 19,2025

The approved product is bioequivalent to the reference listed drug (RLD), Imodium A-D Tablets, 2 mg, marketed by Kenvue Brands LLC (NDA - 019860).

Loperamide Hydrochloride is an anti-diarrheal medication used to manage symptoms of acute and chronic diarrhea, strengthening Marksans Pharma’s portfolio in the US generic pharmaceutical market.

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

The company’s consolidated net profit rose 1.6% to Rs 98.25 crore on 12.2% jump in revenue from operations to Rs 720.41 crore in Q2 FY26 over Q2 FY25.

Shares of Marksans Pharma fell 1.46% to Rs 189.50 on the BSE.